Tumour Registry Breast Cancer (TMK)
Status
Conditions
Study type
Funder types
Identifiers
Details and patient eligibility
About
The registry aims to collect and analyse information on the antineoplastic treatment of breast cancer in daily routine practice of office-based and clinic-based medical oncologists in Germany.
Full description
The TMK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of breast cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
The impact of nutrition (MaNut) and physical activity (MaNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (MaTox) and the multiple patient-reported outcomes (MaLife).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Breast cancer
- 18 years and older
- Antineoplastic or antihormonal treatment
Exclusion criteria
- No breast cancer
- Below 18 years
- No antineoplastic or antihormonal treatment
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal